167 related articles for article (PubMed ID: 28582797)
1. The detrimental impact of persistent vs an isolated occurrence of de novo donor-specific antibodies on intermediate-term renal transplant outcomes.
Loucks-DeVos JM; Eagar TN; Gaber AO; Patel SJ; Teeter LD; Graviss EA; Knight RJ
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28582797
[TBL] [Abstract][Full Text] [Related]
2. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
[TBL] [Abstract][Full Text] [Related]
4. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
[TBL] [Abstract][Full Text] [Related]
5. Role of de novo donor-specific anti-HLA antibodies in kidney graft failure: A case-control study.
Castro A; Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
HLA; 2017 Nov; 90(5):267-275. PubMed ID: 28776960
[TBL] [Abstract][Full Text] [Related]
6. Results of early treatment for de novo donor-specific antibodies in pediatric kidney transplant recipients in a cross-sectional and longitudinal cohort.
Charnaya O; Tuchman S; Moudgil A
Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29356221
[TBL] [Abstract][Full Text] [Related]
7. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.
Wiebe C; Gibson IW; Blydt-Hansen TD; Pochinco D; Birk PE; Ho J; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
Am J Transplant; 2015 Nov; 15(11):2921-30. PubMed ID: 26096305
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
[TBL] [Abstract][Full Text] [Related]
9. Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant Recipients.
Engen RM; Park GE; Schumacher CS; Gimferrer I; Warner P; Finn LS; Weiss NS; Smith JM
Transplantation; 2018 Dec; 102(12):2072-2079. PubMed ID: 29863579
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Pancreas Transplant Recipients With De Novo Donor-specific Antibodies.
Parajuli S; Alagusundaramoorthy S; Aziz F; Garg N; Redfield RR; Sollinger H; Kaufman D; Djamali A; Odorico J; Mandelbrot D
Transplantation; 2019 Feb; 103(2):435-440. PubMed ID: 29994978
[TBL] [Abstract][Full Text] [Related]
11. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
[TBL] [Abstract][Full Text] [Related]
12. Influence of de novo donor-specific antibody on early renal allograft function recovery.
Zheng J; Xue W; Jing X; Hou J; Tian X; Tian P; Ding X; Pan X; Yan H; Feng X; Xiang H; Li Y; Ding C
Ren Fail; 2015 Apr; 37(3):462-8. PubMed ID: 25697229
[TBL] [Abstract][Full Text] [Related]
13. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
[TBL] [Abstract][Full Text] [Related]
14. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
[TBL] [Abstract][Full Text] [Related]
15. De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
Moayedi Y; Fan CS; Tinckam KJ; Ross HJ; McCaughan JA
Clin Transplant; 2018 Nov; 32(11):e13416. PubMed ID: 30276870
[TBL] [Abstract][Full Text] [Related]
16. Utility of protocol kidney biopsies for de novo donor-specific antibodies.
Parajuli S; Reville PK; Ellis TM; Djamali A; Mandelbrot DA
Am J Transplant; 2017 Dec; 17(12):3210-3218. PubMed ID: 28805293
[TBL] [Abstract][Full Text] [Related]
17. Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy.
Messina M; Ariaudo C; Praticò Barbato L; Beltramo S; Mazzucco G; Amoroso A; Ranghino A; Cantaluppi V; Fop F; Segoloni GP; Biancone L
Transpl Immunol; 2015 Sep; 33(1):7-12. PubMed ID: 26160049
[TBL] [Abstract][Full Text] [Related]
18. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
19. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.
Wiebe C; Gibson IW; Blydt-Hansen TD; Karpinski M; Ho J; Storsley LJ; Goldberg A; Birk PE; Rush DN; Nickerson PW
Am J Transplant; 2012 May; 12(5):1157-67. PubMed ID: 22429309
[TBL] [Abstract][Full Text] [Related]
20. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
